论文部分内容阅读
目的观察分析胰岛素类似物联合应用治疗2型糖尿病的疗效。方法将60例门诊或病房2型糖尿病患者分为门冬胰岛素组和那格列奈组,每组30例。门冬胰岛素组给予甘精胰岛素联合门冬胰岛素,那格列奈组给予甘精胰岛素联合那格列奈。治疗前后分别检测患者空腹(FBG)、餐后2 h(2 h PBG)和夜间(凌晨2∶00)血糖,治疗后统计两组患者低血糖发生情况。结果门冬胰岛素组和那格列奈组患者各自治疗后FBG、2 h PBG和夜间血糖与治疗前比较均明显降低,差异有统计学意义(P<0.05);治疗后门冬胰岛素组患者FBG、2 h PBG和夜间血糖控制情况优于那格列奈组(P<0.05);门冬胰岛素组低血糖发生率低于那格列奈组(P<0.05)。结论甘精胰岛素联合门冬胰岛素控制患者血糖效果优于甘精胰岛素联合那格列奈,可能更能降低患者低血糖发生率。
Objective To observe and analyze the efficacy of insulin analogue combined with type 2 diabetes mellitus. Methods Sixty outpatients or patients with type 2 diabetes mellitus were divided into aspart insulin group and nateglinide group, 30 cases in each group. Aspart insulin group given insulin glargine combined with insulin aspart, nateglinide group given insulin glargine combined with nateglinide. Fasting blood glucose (FBG), postprandial 2 h (2 h PBG) and nighttime (2:00 am) blood glucose were measured before and after treatment. The incidence of hypoglycemia in both groups were measured after treatment. Results Aspirin group and nateglinide group were significantly lower FBG, 2 h PBG and nocturnal blood glucose compared with before treatment, the difference was statistically significant (P <0.05); After treatment insulin aspart group patients FBG, 2 h PBG and nocturnal glycemic control were better than nateglinide (P <0.05); the incidence of hypoglycemia in insulin aspart was lower than nateglinide (P <0.05). Conclusion Glargine and insulin aspart control in patients with glycemic control better than glargine combined with nateglinide, may be more able to reduce the incidence of hypoglycemia in patients.